EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

HER2 + advanced gastric cancer: Current state and opportunities (Review)

Hui-Hui Hu, Sai-Qi Wang, Huichen Zhao, Zhe-Sheng Chen, Xiaojing Shi, Xiao-Bing Chen

International Journal of Oncology · 19.02.2024 · 64 (4)

DOI: 10.3892/ijo.2024.5624 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Oncology, online erschienen am 19.02.2024. Verfasst von Hui-Hui Hu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Zhengzhou Key Laboratory for Precision Therapy of Gastrointestinal Cancer, Department of Oncology, Henan Engineering Research Center of Precision The…. Hauptthemen laut MEDLINE: Stomach Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 161 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human epidermal growth factor receptor 2 (HER2)+ gastric cancer (GC) is a distinct subtype of GC, accounting for 10‑20% of all cases of GC. Although the development of the anti‑HER2 monoclonal antibody trastuzumab has markedly improved response rates and prognosis of patients with HER2+ advanced GC (AGC), drug resistance remains a considerable challenge. Therefore, dynamic monitoring of HER2 expression levels can facilitate the identification of patients who may benefit from targeted therapy. Besides trastuzumab, DS‑8201 and RC48 have been applied in the treatment of HER2+ AGC, and several novel anti‑HER2 therapies are undergoing preclinical/clinical trials. At present, combination immunotherapy with anti‑HER2 agents is used as the first‑line treatment of this disease subtype. New promising approaches such as chimeric antigen receptor T‑cell immunotherapy and cancer vaccines are also being investigated for their potential to improve clinical outcomes. The current review provides new insights that will guide the future application of anti‑HER2 therapy by summarizing research progress on targeted therapy drugs for HER2+ AGC and combination treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsAntineoplastic AgentsHumansTrastuzumabErb-b2 Receptor Tyrosine KinasesPrognosisImmunotherapy

Stichwörter der Autor:innen

advanced gastric cancerhuman epidermal growth factor receptor 2immunotherapytargeted therapytrastuzumab

Substanzen

TrastuzumabErb-b2 Receptor Tyrosine KinasesAntineoplastic Agents

Autor:innen und Institutionen

  • Zhengzhou Key Laboratory for Precision Therapy of Gastrointestinal Cancer, Department of Oncology, Henan Engineering Research Center of Precision Therapy of Gastrointestinal Cancer, The Affiliated Cancer Hospital of Zhe…
  • Department of Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China.
  • College of Pharmacy and Health Sciences, St. John's University, Queens, NY 11439, USA.
  • The Academy of Medical Sciences of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China.

Zitieren

APA

Hu, H. H., Wang, S. Q., Zhao, H., Chen, Z. S., Shi, X., & Chen, X. B. (2024). HER2 + advanced gastric cancer: Current state and opportunities (Review). International Journal of Oncology, 64(4). https://doi.org/10.3892/ijo.2024.5624

Vancouver

Hu HH, Wang SQ, Zhao H, Chen ZS, Shi X, Chen XB. HER2 + advanced gastric cancer: Current state and opportunities (Review). International Journal of Oncology. 2024;64(4). doi:10.3892/ijo.2024.5624

BibTeX
@article{Hu2024,
  author = {Hu, Hui-Hui and Wang, Sai-Qi and Zhao, Huichen and Chen, Zhe-Sheng and Shi, Xiaojing and Chen, Xiao-Bing},
  title = {HER2 + advanced gastric cancer: Current state and opportunities (Review)},
  journal = {International Journal of Oncology},
  year = {2024},
  volume = {64},
  number = {4},
  doi = {10.3892/ijo.2024.5624}
}
Kostenlos starten →